| 1 |
Burayzat S, Al-tamimi M, Barqawi M, Massadi MS, Abu-raideh J, Albalawi H, Khasawneh AI, Himsawi N, Barber M. Antimicrobial Resistance Molecular Mechanisms of Helicobacter pylori in Jordanian Children: A Cross-Sectional Observational Study. Antibiotics 2023;12:618. [DOI: 10.3390/antibiotics12030618] [Reference Citation Analysis]
|
| 2 |
Fekadu S, Engiso H, Seyfe S, Iizasa H, Godebo A, Deyno S, Yoshiyama H. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis. BMC Gastroenterol 2023;23:55. [PMID: 36882697 DOI: 10.1186/s12876-023-02707-5] [Reference Citation Analysis]
|
| 3 |
Goldberg L, Amrick TJ. Successful Eradication of Helicobacter pylori with 5-Day Concomitant Treatment. GastroHep 2022;2022:1-4. [DOI: 10.1155/2022/1211329] [Reference Citation Analysis]
|
| 4 |
Shah S, Hubscher E, Pelletier C, Jacob R, Vinals L, Yadlapati R. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol 2022;16:341-57. [PMID: 35315732 DOI: 10.1080/17474124.2022.2056015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Ho C, Liu T, Lin Y, Chen Y, Chen M, Wang H, Liou T. Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection. Microorganisms 2022;10:415. [DOI: 10.3390/microorganisms10020415] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 6 |
Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter 2022;27:e12860. [PMID: 34708484 DOI: 10.1111/hel.12860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 7 |
Maioli ME, Frange RFN, Grion CMC, Delfino VDA. Helicobacter pylori eradication in renal transplant candidates. J Bras Nefrol 2022:S0101-28002022005001401. [PMID: 35014666 DOI: 10.1590/2175-8239-JBN-2021-0097] [Reference Citation Analysis]
|
| 8 |
Kim J, Gong EJ, Seo M, Seo HI, Park JK, Lee SJ, Han KH, Jeong WJ, Kim YD, Cheon GJ. Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection. JPM 2022;12:56. [DOI: 10.3390/jpm12010056] [Reference Citation Analysis]
|
| 9 |
Lee YD, Kim SE, Park SJ, Park MI, Moon W, Kim JH, Jung K, Song J. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection. Korean J Gastroenterol 2020;76:142-9. [PMID: 32969362 DOI: 10.4166/kjg.2020.76.3.142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 2021;40:420-44. [PMID: 34219211 DOI: 10.1007/s12664-021-01186-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 11 |
Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori. Gut Liver 2021;15:528-36. [PMID: 33376228 DOI: 10.5009/gnl20225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Dos Santos Viana I, Cordeiro Santos ML, Santos Marques H, Lima de Souza Gonçalves V, Bittencourt de Brito B, França da Silva FA, Oliveira E Silva N, Dantas Pinheiro F, Fernandes Teixeira A, Tanajura Costa D, Oliveira Souza B, Lima Souza C, Vasconcelos Oliveira M, Freire de Melo F. Vaccine development against Helicobacter pylori: from ideal antigens to the current landscape. Expert Rev Vaccines 2021;20:989-99. [PMID: 34139141 DOI: 10.1080/14760584.2021.1945450] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Jonaitis P, Kupcinskas J, Nyssen OP, Puig I, Gisbert JP, Jonaitis L. Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Medicina (Kaunas) 2021;57:642. [PMID: 34201428 DOI: 10.3390/medicina57070642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Lee JW, Kim SJ, Choi CW, Kim HJ, Kang DH, Kim HW, Park SB, Nam HS, Ryu DG. Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation. Medicine (Baltimore) 2021;100:e26133. [PMID: 34032763 DOI: 10.1097/MD.0000000000026133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Kakiuchi T, Matsuo M, Endo H, Sakata Y, Esaki M, Noda T, Imamura I, Hashiguchi K, Ogata S, Fujioka Y, Hanada K, Fukuda K, Yoshimura M, Kajiwara T, Yamamoto K, Yamaguchi D, Kawakubo H, Akashi T, Sumino M, Matsunaga K, Muro E, Kuwahara A, Taniguchi K, Fukuyama K, Watanabe A, Takamori A, Okuda M, Yamanouchi K, Fujimoto K. Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study. Helicobacter 2021;26:e12776. [PMID: 33368891 DOI: 10.1111/hel.12776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Kim SE, Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M, Korean College of Helicobacter and Upper Gastrointesinal Research. A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:48-58. [DOI: 10.7704/kjhugr.2020.0052] [Reference Citation Analysis]
|
| 17 |
Peña-Galo E, Gotor J, Harb Y, Alonso M, Alcedo J. Socioeconomic and demographic factors associated with failure in Helicobacter pylori eradication using the standard triple therapy. Gastroenterol Hepatol Bed Bench 2021;14:53-8. [PMID: 33868610] [Reference Citation Analysis]
|
| 18 |
Vörhendi N, Soós A, Anne Engh M, Tinusz B, Szakács Z, Pécsi D, Mikó A, Sarlós P, Hegyi P, Eröss B. Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding: a systematic review and network meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820965324. [PMID: 33403002 DOI: 10.1177/1756284820965324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 19 |
Hussein NR, Mirkhan SA, Ramadhan AA, Issa RS, Naqid IA, Yassin B, Hasso SS, Salih RS, Mahmood SA. Levofloxacin-Based Regimen Versus Bismuth Quadruple Regimen for Helicobacter pylori Eradication in Kurdistan Region, Iraq. Avicenna J Clin Microbiol Infect 2020;7:81-84. [DOI: 10.34172/ajcmi.2020.18] [Reference Citation Analysis]
|
| 20 |
Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 21 |
Lee GH, Lee KM, Shin SJ, Kang JK, Noh CK, Kim JH, Lim SG. Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection. Korean J Intern Med 2020;35:1094-103. [PMID: 32921010 DOI: 10.3904/kjim.2020.174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 22 |
Di J, Zhang J, Cao L, Huang TT, Zhang JX, Mi YN, Xiao X, Yan PP, Wu ML, Yao T, Liu DZ, Liu J, Cao YX. Hydrogen Peroxide-Mediated Oxygen Enrichment Eradicates Helicobacter pylori In Vitro and In Vivo. Antimicrob Agents Chemother 2020;64:e02192-19. [PMID: 32071054 DOI: 10.1128/AAC.02192-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Gao C, Du SY, Fang L, Fan YH, Song AP, Chen H. Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance. Infect Drug Resist 2020;13:69-79. [PMID: 32021321 DOI: 10.2147/IDR.S232169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 24 |
Yatheendranathan GD, Ankaiya S, Kumar JL. Comparative Study between Two Triple-therapy Regimens in Treating Helicobacter pylori: Related Peptic Ulcer Disease. SBV Journal of Basic, Clinical and Applied Health Science 2019;2:108-111. [DOI: 10.5005/jp-journals-10082-02222] [Reference Citation Analysis]
|
| 25 |
Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019;19:447. [PMID: 31113384 DOI: 10.1186/s12879-019-4085-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 26 |
Hsieh MS, Liu CJ, Hsu WH, Li CJ, Tsai PY, Hu HM, Shih HY, Lu CY, Yu FJ, Kuo FC, Wu DC, Kuo CH. Gastric juice-based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection. Helicobacter 2019;24:e12568. [PMID: 30821043 DOI: 10.1111/hel.12568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 27 |
Jung DH, Kim JH, Jeong SJ, Park SY, Kang IM, Lee KH, Song YG. Peptide Nucleic Acid Probe-Based Analysis as a New Detection Method for Clarithromycin Resistance in Helicobacter pylori. Gut Liver. 2018;12:641-647. [PMID: 30037168 DOI: 10.5009/gnl18111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 28 |
Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study. Turk J Gastroenterol 2018;29:549-54. [PMID: 30260776 DOI: 10.5152/tjg.2018.17707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 29 |
Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy. Korean J Gastroenterol 2019;73:26. [DOI: 10.4166/kjg.2019.73.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 30 |
Lee KH, Park SY, Jeong SJ, Jung DH, Kim JH, Jeong SH, Kang IM, Song YG. Can Aminoglycosides Be Used as a New Treatment for Helicobacter pylori? In vitro Activity of Recently Isolated Helicobacter pylori. Infect Chemother 2019;51:10-20. [PMID: 30941933 DOI: 10.3947/ic.2019.51.1.10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 31 |
Park CG, Kim S, Lee EJ, Jeon HS, Han S. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: A prospective, observational study. Medicine (Baltimore) 2018;97:e11835. [PMID: 30113472 DOI: 10.1097/MD.0000000000011835] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 32 |
Chang YW, Ko WJ, Oh CH, Park YM, Oh SJ, Moon JR, Cho JH, Kim JW, Jang JY. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. Korean J Intern Med 2019;34:1022-9. [PMID: 29898576 DOI: 10.3904/kjim.2018.054] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 33 |
Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 34 |
Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice. Gastroenterología y Hepatología (English Edition) 2018;41:145-152. [DOI: 10.1016/j.gastre.2018.03.004] [Reference Citation Analysis]
|
| 35 |
Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018;41:145-52. [DOI: 10.1016/j.gastrohep.2017.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 36 |
Li H, Liang X, Chen Q, Zhang W, Lu H. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. Scand J Gastroenterol 2018;53:130-3. [PMID: 29214879 DOI: 10.1080/00365521.2017.1413132] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 37 |
Yilmaz B, Koseoglu H, Coskun Y, Deveci M, Kekilli M. Comparison between different first-line therapy protocols in eradicating Helicobacter pylori in a region with high clarithromycin resistance. Prz Gastroenterol 2018;13:150-6. [PMID: 30002775 DOI: 10.5114/pg.2018.72732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 38 |
Eisdorfer I, Shalev V, Goren S, Chodick G, Muhsen K. Sex differences in urea breath test results for the diagnosis of Helicobacter pylori infection: a large cross-sectional study. Biol Sex Differ 2018;9:1. [PMID: 29291751 DOI: 10.1186/s13293-017-0161-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 39 |
Ramas M, Donday MG, Mcnicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterología y Hepatología (English Edition) 2017;40:658-662. [DOI: 10.1016/j.gastre.2017.05.010] [Reference Citation Analysis]
|
| 40 |
Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Helicobacter pylori Eradication]. Korean J Gastroenterol 2017;70:72-80. [PMID: 28830132 DOI: 10.4166/kjg.2017.70.2.72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 41 |
Ramas M, Donday MG, McNicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterol Hepatol 2017;40:658-62. [PMID: 28780968 DOI: 10.1016/j.gastrohep.2017.05.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 42 |
Branquinho D, Almeida N, Gregório C, Cabral JE, Casela A, Donato MM, Tomé L. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? BMC Gastroenterol 2017;17:31. [PMID: 28202013 DOI: 10.1186/s12876-017-0589-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 43 |
Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 44 |
Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, Moon CM, Kim SE, Jung HK, Jung SA. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. BMC Gastroenterol 2017;17:16. [PMID: 28109257 DOI: 10.1186/s12876-017-0579-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 45 |
Yoo J, Yu YJ, Cho G, Oh H, Oh SH, Kim TH, Oh JH. Helicobacter pylori Eradication Rate in Patients with Diabetes. Korean J Helicobacter Up Gastrointest Res 2017;17:83. [DOI: 10.7704/kjhugr.2017.17.2.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 46 |
Tsai CE, Liang CM, Lee CH, Kuo YH, Wu KL, Chiu YC, Tai WC, Chuah SK. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci 2016;32:397-402. [PMID: 27523452 DOI: 10.1016/j.kjms.2016.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 47 |
Chi ZC. Update on prevention and treatment of Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2016; 24(16): 2454-2462 [DOI: 10.11569/wcjd.v24.i16.2454] [Reference Citation Analysis]
|
| 48 |
Hu B, Zhao F, Wang S, Olszewski MA, Bian H, Wu Y, Kong M, Xu L, Miao Y, Fang Y, Yang C, Zhao H, Zhang Y. A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis. Future Microbiol 2016;11:1261-78. [PMID: 27023051 DOI: 10.2217/fmb-2016-0023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 49 |
Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Seo KI, Lim SK, Jung JK, Kim HJ, Yeo GE, Jeon SC, Cho DS, Han YJ. The Influence of Iron Deficiency onHelicobacter pyloriEradication. Korean J Helicobacter Up Gastrointest Res 2016;16:82. [DOI: 10.7704/kjhugr.2016.16.2.82] [Reference Citation Analysis]
|
| 50 |
Bang CS, Baik GH. Time to learn from the past and prepare for the future in Helicobacter pylori eradication. Korean J Intern Med 2015;30:789-91. [PMID: 26552453 DOI: 10.3904/kjim.2015.30.6.789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
